News of Orthocell’s record-breaking quarterly and full year revenue has been published in a Special Report in The Australian Business Review.<\/p>\n
The article, “Investors are all ears as Orthocell\u2019s nerve and tissue solutions deliver record revenue<\/em>” highlights the steady sales growth for both Orthocell\u2019s market-leading products, Striate+ and Remplir, and the Company’s plans to establish its position as a market leader, globally.<\/p>\n Here’s an excerpt:<\/p>\n “The global market opportunity for these two products alone is estimated to be somewhere around the US$3 billion mark \u2013 a number which can only grow as target populations age and demand for nerve treatments spike.<\/p>\n Striate+ is already a market-leading solution in maturing markets, both at home and across Europe, the UK and in the US, while (Remplir) Orthocell\u2019s nerve repair solution is currently only available at home and in New Zealand.<\/p>\n According to Paul Anderson, Orthocell aims to secure a 20% market share for Striate+, which he says would generate circa $50 million in recurring revenue.”<\/p>\n